GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization

Abstract

A recent study showed that sarcosine may be potentially useful for the diagnosis and prognosis of prostate cancer (PCa). The aim of this study was to validate diagnostic value of sarcosine for PCa, to evaluate urine metabolomic profiles in patients with PCa in comparison of non-cancerous control, and to further explore the other potential metabolic biomarkers for PCa. Isotope dilution gas chromatography/mass spectrometry (ID GC/MS) metabolomic approach was applied to evaluate sarcosine using [methyl-D(3)]-sarcosine as an internal standard. Microwave-assisted derivatization (MAD) together with GC/MS was utilized to obtain the urinary metabolomic information in 20 PCa patients compared with eight patients with benign prostate hypertrophy and 20 healthy men. Acquired metabolomic data were analyzed using a two-sample t test. Diagnostic models for PCa were constructed using principal component analysis and were assessed with receiver-operating characteristic curves. Results showed that the urinary sarcosine level has no statistical difference between the PCa group and the control group. In addition, nine metabolomic markers between the PCa group and the healthy male group were selected, which constructed a diagnostic model with a high area under the curve value of 0.9425. We conclude that although urinary sarcosine value has limited potential in the diagnostic algorithm of PCa, urinary metabolomic panel based on GC/MS assay following MAD may potentially become a diagnostic tool for PCa.

Metabolic alterations in the sera of Chinese patients with mild persistent asthma: a GC-MS-based metabolomics analysis

“…It utilizes fundamental analytical techniques to probe the chemical fingerprint of the samples and makes use of multivariate statistical analyses to search for diseaserelated potential biomarkers and metabolic pathways [15][16][17][18] . To date, both nuclear magnetic resonance (NMR) [8,[19][20][21][22] and mass spectrometry (MS)-based [23,24] metabolomics techniques have been used to analyze respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.…”

Is sarcosine a biomarker for prostate cancer?

“…A recent study by Wu et al [16] used isotope dilution GC/MS and deuterated sarcosine internal standard to validate the role of sarcosine as a prostate cancer biomarker. They studied the urine obtained from 20 prostate cancer patients, eight patients with benign prostate hypertrophy and 20 healthy men.…”

Metabolomic profiling of hormone-dependent cancers: a bird's eye view

“…In fact, one article reports that the levels of nine metabolites differentiated between PCa and normal prostate tissue with an AUC of 0.94. This discriminatory power fell to only 0.83 when five of the nine metabolites were utilized in the model to distinguish between PCa and benign prostatic hyperplasia [48]. In another study of urinary sediment, sarcosine levels were higher in biopsy positive prostate cancer patients relative to biopsy negative controls with a modest AUC ranging between 0.63–0.7 across multiple studies [29, 30, 49, 50].…”